Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Fuster

Showing results (71-80 of 512) with videos related to

Pageof 52
Sort By:
Thrombosis and Haemostasis|April 30, 1978
The von Willebrand pig as a model for atherosclerosis researchV Fuster, E J Bowie
Acta Medica Scandinavica. Supplementum|January 1, 1980
Resistance to atherosclerosis in pigs with von Willebrand's diseaseE J Bowie, V Fuster
Mayo Clinic Proceedings|March 1, 1981
10. Antithrombotic therapy: role of platelet-inhibitor drugs. II. Pharmacologic effects of platelet-inhibitor drugs (second of three parts)V Fuster, J H Chesebro
Mayo Clinic Proceedings|February 1, 1981
Antithrombotic therapy: role of platelet-inhibitor drugs. I. Current concepts of thrombogenesis: role of platelets. (first of three parts)V Fuster, J H Chesebro
Progress in Cardiovascular Diseases|December 24, 1997
Thrombosis, antithrombotic agents, and the antithrombotic approach in cardiac diseaseA E Schussheim, V Fuster
Cardiovascular Research|May 26, 1999
Pathophysiology and clinical significance of atherosclerotic plaque ruptureD E Gutstein, V Fuster
Circulation|November 1, 1996
Optimal antithrombotic therapy for mechanical prosthetic heart valvesJ H Chesebro, V Fuster
The Mount Sinai Journal of Medicine, New York|October 1, 1996
Fifty years of experience with antithrombotic therapy in cardiac disease. A 1996 approach based on pathogenesis and riskR S Freudenberger, V Fuster
The Mount Sinai Journal of Medicine, New York|September 1, 1995
The three mechanisms for coronary artery disease progression: insights into future managementM A McLaughlin, V Fuster
European Heart Journal|July 1, 1995
Regression or stabilization of atherosclerosis means regression or stabilization of what we don't see in the arteriogramV Fuster, J J Badimon
Pageof 52

Showing results (71-80 of 512) with videos related to

Sort By:
Pageof 52
Thrombosis and Haemostasis|April 30, 1978
The von Willebrand pig as a model for atherosclerosis researchV Fuster, E J Bowie
Acta Medica Scandinavica. Supplementum|January 1, 1980
Resistance to atherosclerosis in pigs with von Willebrand's diseaseE J Bowie, V Fuster
Mayo Clinic Proceedings|March 1, 1981
10. Antithrombotic therapy: role of platelet-inhibitor drugs. II. Pharmacologic effects of platelet-inhibitor drugs (second of three parts)V Fuster, J H Chesebro
Mayo Clinic Proceedings|February 1, 1981
Antithrombotic therapy: role of platelet-inhibitor drugs. I. Current concepts of thrombogenesis: role of platelets. (first of three parts)V Fuster, J H Chesebro
Progress in Cardiovascular Diseases|December 24, 1997
Thrombosis, antithrombotic agents, and the antithrombotic approach in cardiac diseaseA E Schussheim, V Fuster
Cardiovascular Research|May 26, 1999
Pathophysiology and clinical significance of atherosclerotic plaque ruptureD E Gutstein, V Fuster
Circulation|November 1, 1996
Optimal antithrombotic therapy for mechanical prosthetic heart valvesJ H Chesebro, V Fuster
The Mount Sinai Journal of Medicine, New York|October 1, 1996
Fifty years of experience with antithrombotic therapy in cardiac disease. A 1996 approach based on pathogenesis and riskR S Freudenberger, V Fuster
The Mount Sinai Journal of Medicine, New York|September 1, 1995
The three mechanisms for coronary artery disease progression: insights into future managementM A McLaughlin, V Fuster
European Heart Journal|July 1, 1995
Regression or stabilization of atherosclerosis means regression or stabilization of what we don't see in the arteriogramV Fuster, J J Badimon
Pageof 52